Emerson Electric (EMR)
NYSEIndustrialsIndustrial - MachinerySnapshot 2026-10-30
$164.94-3.40%
Close 2026-10-30 · 1-day change
NYSEIndustrialsIndustrial - MachinerySnapshot 2026-10-30
Research Workspace
Put EMR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Electrical Components & Equipment is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve free cash flow of $3.5B-$3.6B: Direct metric needs a verified mapping.
View ThesisRevenue is growing steadily — about 5% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on earnings delivery, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 21% growth a year, above the roughly 7% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskEMR's case rests on steady industrial performance, with revenue growth accelerating from 5% to 7%. The latest recorded result beat estimates, while management guided to approximately $3.6 billion in free cash flow. EMR trades at 27× P/E versus a 36× peer median and its own 24× history. Despite the peer gap, the market is pricing in more growth than our forecast. The specific risk is weak cash backing for reported profits, despite the free cash flow guidance. Our model puts the next-quarter miss probability near 19%. Peer multiples imply a price about 23% below where it trades; the thesis is on watch.
Trailing returns as of 2026-10-30. EMR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 31 analysts currently covering EMR (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for EMR in the last 4 months.
Continue this research
Compare EMR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EMR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Electrical Components & Equipment — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put EMR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete portfolio transformation with AspenTech acquisition
New deal supports portfolio transformation and growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $164.94
The last 12 months of price, then the range of analyst 12-month targets from today’s $164.94.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
CEO selling shares may raise concerns about leadership confidence.
Advances: Achieve $3.5B-$3.6B free cash flow in 2026
Increased EPS and free cash flow targets support growth objectives.
Advances: Achieve $3.5B-$3.6B free cash flow in 2026
Strong demand supports free cash flow target.
Advances: Maintain EPS guidance of $4.79-$4.89 for 2026
Raising outlook confirms EPS guidance sustainability.
Advances: Return $2.2B to shareholders in 2026
Strong automation demand aids shareholder returns.
Advances: Achieve $3.5B-$3.6B free cash flow in 2026
Sales beat supports free cash flow expectations.
Threatens: Maintain EPS guidance of $4.79-$4.89 for 2026
Earnings miss raises concerns over EPS guidance.
